Sanofi (NYSE:SNY) reported earnings from the quarter that were below analyst expectations, driven (in part) by a strong euro and currency conversion issues. That said, there were other disappointments as well -- Lantus, Sanofi's flagship insulin product, was up 13.5% in constant currencies to just under 1.5 billion euros, a little lighter than analysts had anticipated.

Nonetheless, Sanofi's management is guiding for 4% to 7% revenue growth (at constant currencies) over the next year, driven by several potential exciting pipeline candidates, including U-300 and alirocumab.

In this segment from Tuesday's Market Checkup, Motley Fool health care analysts David Williamson and Michael Douglass break down the earnings and what investors should watch for moving forward at Sanofi.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That’s beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor’s portfolio. To see our free report on these stocks, just click here now.

David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.